Evaluation of the Xpa-Deficient Transgenic Mouse Model for Short-Term Carcinogenicity Testing: 9-Month Studies with Haloperidol,Reserpine,Phenacetin,and D-Mannitol

Abstract

As part of the international evaluation program coordinated by ILSI/HESI, the potential of DNA repair deficient Xpa-/- mice and the double knockout Xpa-/-.p53+/- mice for short term carcinogenicity assays was evaluated. For comparison also wild-type C57BL/6 mice (WT) were included in these studies. Four test compounds were administered to groups of 15 male and 15 female Xpa-/- mice, Xpa-/-.p53+/- mice and WT mice for 39 weeks. The model compounds investigated were haloperidol, reserpine (nongenotoxic rodent carcinogens, putative human noncarcinogens), phenacetin (genotoxic rodent carcinogen, suspected human carcinogen), and D-mannitol (noncarcinogen in rodents and humans). The test compounds were administered as admixture to rodent diet at levels up to 25 mg/kg diet for haloperidol, 7.5 mg/kg diet for reserpine, 0.75% for phenacetin, and 10% for D-mannitol. These levels included the maximum tolerable dose (MTD). Survival was not affected with any of the test compounds. Haloperidol, reserpine and D-mannitol were negative in the carcinogenicity assay with Xpa-/- and Xpa-/- .p53+/- mice, showing low and comparable tumor incidences in controls and high-dose animals. The results obtained with phenacetin may be designated equivocal in Xpa-/- .p53+/- mice, based on the occurrence of a single rare tumor in the target organ (kidney) accompanied by a low incidence of hyperplastic renal lesions and a high incidence of karyomegaly. These results are in agreement with the currently known carcinogenic potential of the 4 test compounds in humans.

Keywords

Xpa Xpa/p53 knockout mice carcinogens carcinogenicity testing DNA repair deficient.

References

Bahneman, R. , Jacobs, M. , Karbe, E. , Kaufmann, W. , Morawietz, G. , and Nolte, T. (1995). RITA registry of industrial toxicology animal-data-guides for organ sampling and trimming procedures in rats. Exp Toxicol Pathol 47, 247—66.

Berg, R.J.W. , de Vries, A. , Van Steeg, H. , and De Gruijl, F.R. (1997). Relative susceptibilities of Xpa knockout mice, and their heterozygous, and wild-type littermates to UVB-induced skin cancer . Cancer Res 57, 581—4.

de Vries, A. , Van Oostrum, C. Th. M. , Dortant, P.M. , Beems, R.B. , Van Kreijl, C.F. , Capel, P.J.A. , and Van Steeg, H. (1997). Spontaneous liver tumours and benzo[a]pyrene-induced lymphomas in Xpa deficient mice. Molec Carcinogen 19, 46—53.

de Vries, A. , Van Oostrum, C. Th. M. , Hofhuis, F.M.A. , Dortant, P.M. , Berg, R.J.W. , De Gruijl, F.R. , Wester, P.W. , Van Kreijl, C.F. , Capel, P.J.A. , Van Steeg, H. , and Verbeek, S.J. (1995). Increased susceptibility to ultraviolet-B and carcinogenesis of mice lacking the DNA excision repair gene Xpa. Nature 337, 169—73.

IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some Pharmaceutical Drugs (1980). IARC Monographs 24, 211—41.

IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Overall Evaluations of Carcinogenicity: An updating of IARC Monographs volumes 1 to 42 (1987). IARC Monographs Supplement 7, 310—2.

Lina, B.A.R. , Bos-Kuijpers, M.H.M. , Til, H.P. , and Bär, A. (1996). Chronic toxicity and carcinogenicity study of erythritol in rats. Reg Toxicol Pharmacol 24, 264—79.

Mortensen, A. , Bertram, M. , Aarup, V. and Sørensen, I. (2002). Assessment of carcinogenicity of di(2-ethylhexyl)phthalate in a short-term assay using XPA-/- and XPA-/- /p53+/- mice. Toxicol Pathol 30, 188—99.

Nakanishi, K. , Kurata, Y. , Oshima, M. , Fukushima, S. , and Ito, N. (1982). Carcinogenicity of phenacetin: long-term feeding study in B6C3F1 mice. Int J Cancer 29, 439—44.

10.

NTP (1980). National Toxicology Program. Bioassay of reserpine for possible carcinogenicity. NCI Carcinogenesis Technical Report Series 193.

11.

NTP Working group (1982). Carcinogenesis bioassay of D-mannitol in F344/N rats and B6C3F1 mice. National Toxicology Program Technical Report Series 236, 158 p.

12.

Popp, J.A. (2001). Criteria for the evaluation of studies in transgenic models. Toxicol Pathol 29 (suppl) 20—3.

13.

Pritchard, J.B. , French, J.E. , Davis, B.J. , and Haseman, J.K. (2003). The role of transgenic models in carcinogen identification . Environ Health Perspect 111, 444—54.

14.

Robinson, D.E. (1998). The International Life Science Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol Pathol 26, 474—5.

15.

Robinson, D.E. , and McDonald, J.S. (2001). Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. Toxicol Pathol 29 (suppl), 13—19.

16.

Storer, R.D. , French, J.E. , Haseman, J. , Hajian, G. , LeGrand, E.K. , Long, G.G. , Mixson, L.A. , Ochoa, R. , Sagartz, J.E. , and Soper, K.A. (2001). p53+/- Hemizygous knockout mouse: overview of available data. Toxicol Pathol 29 (suppl), 30—50.

17.

Tennant, R.W. , French, J.E. , and Spalding, J.W. (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103, 942—50.

18.

Van Benthem, J. , van den Berg, J.A.H. , Beems, R.B. , van Steeg, H. , and van Kreijl, C.F. (2001). Concurrent positive control studies with p-cresidine and 2-AAF in wild-type, XPA-/- and XPA-/-/p53+/- mice. Toxicologic Pathology 29(suppl), 280—2.

19.

Van Kreijl, C.F. , McAnulty, P.A. , Beems, R.B. , Vynckier, A. , Van Steeg, H. , Fransson-Steen, R. , Alden, C.L. , Forster, R. , Van der Laan, J.-W. , and Vandenberghe, J. (2001). Xpa and Xpa/p53 knockout mice: overview of available data. Toxicol Pathol 29 (suppl), 117—28.

20.

Van Kreijl, C.F. , and Van Steeg, H. (1998). Transgenic mouse models for the identification of human carcinogens: a European perspective. Toxicol Pathol 26, 757—8.

21.

Van Oostrum, C. Th. M. , Boeve, M. , Van den Berg, J. , de Vries, A. , Dollé M.E.T. , Beems, R.B. , Van Kreijl, C.F. , Vijg, J. , and Van Steeg, H. (1999). The effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient Xpa mice. Environ Mol Mutagen 34, 124—30.

22.

Van Steeg, H. , de Vries, A. , Van Oostrum, C. Th. M. , Van Benthem, J. , Beems, R.B. , and Van Kreijl, C.F. (2001). DNA repair-deficientXpaandXpa/p53+/Knock-out mice: nature of the models. Toxicol Pathol 29 (suppl), 109—16.

23.

Van Steeg, H. , Klein, H. , Beems, R.B. , and Van Kreijl, C.F. (1998). Use of DNA repair-deficient Xpa transgenic mice in short-term carcinogenicity testing. Toxicol Pathol 26, 742—9.

24.

Yamamoto, S. , Mitsumorfi, K. , Kodama, Y. , Matsunuma, N. , Manabe, S. , Okamya, H. , Suzuki, H. , Fukada, T. , Sakamaki, Y. , Sunaga, M. , Nomura, G. , Hioki, K. , Wakana, S. , Nomura, T. , and Hayashi, Y. (1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-H-ras gene, than in control non-transgenic mice. Carcinogenesis 17, 2455—61.